Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

2020

Slider News

2020

  • 2020 - 01 - 27

    Helsinn Grants Exclusive Licensing Rights to Berlin-Chemie Menarini, for ONICIT<sup>®</sup>/ALOXI<sup>®</sup> and AKYNZEO<sup>®</sup> in Russia and CIS region

  • 2020 - 03 - 09

    Farmindustria's Campaign for Covid-19

  • 2020 - 03 - 16

    Covid-19: Menarini Group converts production plant to produce and donate disinfectant gel

  • 2020 - 04 - 02

    COVID-19 Menarini Diagnostics: kit for diagnosis in 20 minutes

  • 2020 - 04 - 25

    COVID-19: Menarini continues with further donations and reaches a record production of 100 tonnes of disinfectant gel

  • 2020 - 04 - 29

    Menarini Silicon Biosystems Explores New Application for Circulating Endothelial Cells in COVID-19

  • 2020 - 05 - 04

    Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million

  • 2020 - 05 - 14

    25th EHA Congress: Menarini Ricerche discloses first results from the clinical study on SEL24/MEN1703

  • 2020 - 06 - 05

    Menarini invests 150 million euros in a new pharmaceutical plant in Italy

  • 2020 - 06 - 10

    Menarini Group Completes Acquisition of Stemline Therapeutics

  • 2020 - 06 - 10

    Menarini Group Completes a Solid Year of Operating Performance

  • 2020 - 06 - 25

    Continuous blood glucose monitoring: the Menarini Diagnostics digital “patch” now available!

  • 2020 - 07 - 02

    Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib/II Trial of MEN1611 in Colorectal Cancer

  • 2020 - 07 - 09

    Menarini Ricerche Announces the Latest Findings of its Vaborem™ and Quofenix™ Clinical Studies

  • 2020 - 07 - 23

    Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

  • 2020 - 09 - 01

    Announced the xxiv edition of the international fair play Menarini award

  • 2020 - 09 - 11

    International Fair Play Menarini award 2020

  • 2020 - 09 - 16

    Menarini Ricerche Announces Initiation of Cohort Expansion for the Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia

  • 2020 - 09 - 17

    Menarini Ricerche Announces Dose Escalation Results Of The Clinical Trial Of Men1611 In Breast Cancer

  • 2020 - 09 - 25

    Radius health & Menarini group provide elacestrant update

  • 2020 - 10 - 26

    Press release

  • 2020 - 10 - 26

    Menarini Group: committed to fighting today's covid-19 pandemic with an eye to averting similar health crises in the future

  • 2020 - 11 - 06

    Menarini against cancer: for a child, ‘home’ means family

  • 2020 - 11 - 13

    Chmp adopted positive opinion for elzonris (tagraxofusp), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  • 2020 - 12 - 01

    Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial

  • 2020 - 12 - 07

    Menarini Announces Results from New Preclinical Studies on MEN1611 for the Treatment of Breast Cancer at the 2020 San Antonio Breast Cancer Symposium

  • 2020 - 12 - 16

    Menarini Group awarded the coveted XV Transatlantic Award from American Chamber of Commerce in Italy